RHEO booked zero sales in 1Q06 because docs in Canada stopped advising patients to get rheopheresis treatments three months ago when the phase-3 trial in dry AMD showed no statsig benefit relative to placebo. The CEO today said the falloff in procedures was only temporary. I guess you gotta admire the chutzpah.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.